Back to today’s briefing

Story perspectives

Novartis' Pluvicto™ Boosts Survival in Prostate Cancer Trial

6/2/2025

46 4

Summary

Story summary

Novartis has unveiled promising interim results from the Phase III PSMAddition trial, revealing that Pluvicto™ paired with standard hormone therapy dramatically enhances radiographic progression-free survival for patients battling PSMA-positive metastatic hormone-sensitive prostate cancer. This breakthrough bolsters Pluvicto's potential for earlier treatment stages, following its recent FDA approval for advanced prostate cancer.

1 of 1

Story summary

Novartis has unveiled promising interim results from the Phase III PSMAddition trial, revealing that Pluvicto™ paired with standard hormone therapy dramatically enhances radiographic progression-free survival for patients battling PSMA-positive metastatic hormone-sensitive prostate cancer. This breakthrough bolsters Pluvicto's potential for earlier treatment stages, following its recent FDA approval for advanced prostate cancer.